Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 462

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 2
Chunk 462
---
 claims and suits that arise from time to time in the ordinary course of our business. Although management currently believes
that resolving claims against the Company, individually or in aggregate, will not have a material adverse impact in the Company’s
consolidated financial statements, these matters are subject to inherent uncertainties and management’s view of these matters may
change in the future. 

NOTE
13 – SEGMENT INFORMATION

The Company
operates as one operating segment. The Company’s chief operating decision maker (“CODM”) is its Chief Financial Officer,
who reviews the financial statements on a consolidated basis. The CODM uses the Company’s long-range plan to allocate resources.
The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using
consolidated loss from operations. 

Significant expenses
within loss from operations, as well as within net loss, include research and development and general and administrative expenses, which
are each separately presented on the Company’s Consolidated Statements of Operations and Comprehensive Loss. Other segment items
within net loss include other income (expense), net.

The Company’s long-lived
assets consist primarily of acquired in-process research and development intangible assets which are located in the United States.

NOTE
14 – SUBSEQUENT EVENTS

Cordstrom License Agreement 

On February 6, 2025, the Company and GOSH entered into a license agreement
for the exclusive commercial use to clinical trial data associated with the Mission EB study investigating the potential of CORDStrom
to treat RDEB in pediatric patients. The Company owns the intellectual property covering CORDStrom, the investigational medicinal product
used in the Mission EB study. In addition, the Company owns intellectual property and maintains trade secret protections covering the
manufacturing of CORDStrom. With this license to the clinical trial data, the Company intends to prepare applications seeking marketing
authorization of CORDStrom for treatment of pediatric RDEB in each of the FDA, EMA, and MHRA. Terms of the license agreement include an
upfront payment of £250,000 (approximately $0.3 million at February 6, 2025) and a single milestone payment of up to £6,000,000
(approximately $7.5 million at February 6, 2025) due on the first to occur marketing authorization to be granted by the FDA, EMA or MHRA.
In addition to these financial terms, the Company has also agreed